How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?

被引:38
作者
Porter, GA [1 ]
Rose, MI [1 ]
Berman, RS [1 ]
Sumner, WE [1 ]
Lee, JE [1 ]
Mansfield, PF [1 ]
Gershenwald, JE [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
D O I
10.1067/msy.2000.107418
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Sentinel lymph node (SLN) biopsy has been shown to reliably identify nodal metastases and the subsequent need for further surgical and adjuvant therapy in patients with cutaneous melanoma. Although SLN identification rates have improved with the addition of radioactive colloid to the blue dye technique, it remains unclear how many lymph nodes should be removed to accurately determine the histologic status of the nodal basin. The objective of this study was to determine the optimal extent of SLN biopsy in these patients. Methods. The records of 633 consecutive patients with melanoma (765 nodal basins) whose primary treatment included SLN biopsy with the use of a combination of blue dye and technetium Tc 99 labeled sulfur colloid were reviewed. SLN biopsy consisted of the removal of all of the blue-stained nodes and all nodes with radiotracer uptake activity of at least twice background. Results. SLN biopsy was successful in 765 of 772 basins (99 %). A mean of 1.9 SLNs (median, 2 SLNs) per basin were excised. At least 3 SLNs were removed in 176 basins (23 %). The overall histologic status of a basin was always established by the first or second SLN harvested (ie, in no patient was the third or subsequent SLN positive when 1 of the first 2 was not). Of the 124 basins containing lymphatic metastases, the SLN that contained the maximal radiotracer uptake (hottest) and/or stained blue was pathologically positive in 118 basins (95 %). In only 6 of the 124 positive basins (5 %) was the sob evidence of occult nodal metastases identified in an SLN that was neither blue-stained nor the hottest. All but 1 of these SLNs had counts that were at least 66% of the hottest node in the basin. Conclusions. With a combined modality approach to SLN biopsy, removal of more than 2 SLNs did not provide information that upstaged any patient with primary melanoma. Removal of additional nonblue SLN(s) that contained radioactive counts of at least twice background but lower than two thirds of the SLNs with maximal radiotracer uptake affected patient management in less than 0.2 % of all cases. These findings may be helpful,in minimizing the extent of surgery and perhaps in reducing the costs and resource use associated with operating room time and pathologic examination.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 20 条
[1]  
Balch CM, 1985, CUTANEOUS MELANOMA C, P321
[2]   Lymphoscintigraphy as a predictor of lymphatic drainage from cutaneous melanoma [J].
Berger, DH ;
Feig, BW ;
Podoloff, D ;
Norman, J ;
Cruse, CW ;
Reintgen, DS ;
Ross, MI .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (03) :247-251
[3]   Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma [J].
Gershenwald, JE ;
Mansfield, PF ;
Lee, JE ;
Ross, MI .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :160-165
[4]   Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma [J].
Gershenwald, JE ;
Colome, MI ;
Lee, JE ;
Mansfield, PF ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2253-2260
[5]   Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid [J].
Gershenwald, JE ;
Tseng, CH ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Bouvet, M ;
Lee, JJ ;
Ross, MI .
SURGERY, 1998, 124 (02) :203-210
[6]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[7]  
KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654
[8]  
LOCKANDERSEN J, 1989, CANCER, V63, P77, DOI 10.1002/1097-0142(19890101)63:1<77::AID-CNCR2820630113>3.0.CO
[9]  
2-2
[10]  
MCMASTERS KM, 1999, SOC SURG ONCOL, pA6